Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SCT650C in axial spondyloarthritis
CTR20243047Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCT650C in ankylosing spondylitis (AS), axial spondyloarthritis (axSpA), sponsored by Sinocelltech Group Limited. Started Aug 2024; status: active.
02
Drugs
SCT650C
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20243047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243047.